The Body Covers: The XIII International AIDS Conference
Switching Protease Inhibitor to Nevirapine Leads to Reversal of Hyperlipidemia and Lipodystrophy
Coverage provided by Alvan Fisher, M.D.
July 12, 2000
This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.
- Switching protease inhibitor (PI) to nevirapine (NVP) leads to reversal of hyperlipidemia and lipodystrophy (Poster, WePeB4197)
Authored by G. Cotton (United Kingdom)
Cotton from Boehringer Ingelheim in the UK did a meta-analysis of six published studies in which the protease inhibitor (PI) component of HAART was switched to nevirapine. Overall 307 patients were enrolled in the studies. There was general consensus in terms of response of serum cholesterol and triglycerides. Total cholesterol fell from a mean of 231 to 210 at 6 months; triglycerides fell from a mean of 295 to 231 at 6 months. In half of the studies, mean cholesterol and mean triglycerides fell to below 200 by 6 months. No significant changes in blood glucose at baseline or after the switch. Three of the five studies reported improvement in body shape. Meanwhile viral suppression was generally maintained.
This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.
|
Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.
|
